我国159家医院前列地尔脂微球注射剂临床使用特征分析

发布时间：2018-04-20 14:12

  本文选题：前列地尔脂微球注射剂 + 平均日剂量　； 参考：《中国药房》2017年14期

【摘要】：目的:为前列地尔脂微球注射剂(Lipo-PGE1)的合理应用和监管提供依据。方法:以来源于全国159家医院医院信息系统中使用Lipo-PGE1的成年住院患者为研究对象,基于频数统计法对Lipo-PGE1的临床使用人群、临床诊断和平均日剂量进行研究。结果:共71 687例成年住院患者纳入统计,使用Lipo-PGE1的男性住院患者明显多于女性,年龄61~75岁的患者最多。患者住院天数主要分布在8~14 d(45.01%),治疗结果以好转为主(68.20%)。Lipo-PGE1临床使用广泛,共涉及871种临床主要诊断,列前3位的是脑梗死(9.06%)、非胰岛素依赖型糖尿病(8.65%)和慢性缺血性心脏病(8.08%)。不同疾病和不同医院Lipo-PGE1的平均日剂量差异较大,且以≤12.5μg居多。结论:Lipo-PGE1作为辅助用药,需要医疗机构及相关监管部门制订合理的监管指标并加强用药指导及用药点评。
[Abstract]:Objective: to provide evidence for rational application and supervision of Lipo-PGE1. Methods: adult inpatients who used Lipo-PGE1 in the hospital information system of 159 hospitals all over the country were studied on the basis of frequency statistics to study the clinical use, clinical diagnosis and average daily dose of Lipo-PGE1. Results: a total of 71,687 adult inpatients were included in the study. Male patients with Lipo-PGE1 were significantly more than women, and the majority of patients were aged 61to 75 years. The days of hospitalization were mainly distributed in 814 days and 45.01%. The treatment results were mainly improved by 68.20% and 68.20%. Lipo-PGE1 was widely used in clinic, involving 871 main clinical diagnoses. The top three were cerebral infarction (9.06), non-insulin dependent diabetes (8.65) and chronic ischemic heart disease (8.08). The average daily dose of Lipo-PGE1 was significantly different among different diseases and hospitals, and was mainly 鈮，

本文编号：1778100